A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
- Sponsor
- Bernstein Clinical Research Center
- Study ID
- NCT00242359
- Phase
- PHASE4
- Status
- Withdrawn
Conditions
- Allergy Induced Asthma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- omalizumab — DRUG
Study Details
Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.
Key Dates
- Start date
- Nov 30, 2005
- Status verified
- Jul 2019
- Primary completion
- Jan 31, 2009
- Completion
- Jan 31, 2009
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: omalizumabopen-label